Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The Rotterdam experience

Seminars in Nuclear Medicine

Volumn 32, Issue 2, 2002, Pages 110-122

  Valkema, Roelf ^a,b,c   De Jong, Marion ^a,b,c   Bakker, Willem H ^a,b,c   Breeman, Wout A P ^a,b,c   Kooij, Peter P M ^a,b,c   Lugtenburg, Pieternella J ^a,b,c   De Jong, Frank H ^a,b,c   Christiansen, Arjan ^a,b,c   Kam, Boen L R ^a,b,c   De Herder, Wouter W ^a,b,c   Stridsberg, Mats ^a,b,c   Lindemans, Jan ^a,b,c   Ensing, Geert ^a,b,c   Krenning, Eric P ^a,b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Department of Tyco Healthcare ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; YTTRIUM 90;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LEUKEMIA; MALE; MYELODYSPLASTIC SYNDROME; NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL; RADIOISOTOPE THERAPY; SPERMATOGENESIS;

EID: 0036231113     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc/2002.31025     Document Type: Article

References (41)

1. 1]-Octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation
2. 3]-octreotide: The Rotterdam experience with more than 1000 patients
3. 1]-octreotide. A case history
4. 1]-octreotide in patients with neuroendocrine tumors
5. 3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy
6. The radiation dose to cells in vitro from intracellular indium-111
7. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide
8. Tolerance of normal tissue to therapeutic irradiation
9. Imaging with octreoscan: Haste makes waste
10. Fragments of chromogranin A are present in the urine of patients with carcinoid turnouts: Development of a specific radioimmunoassay for chromogranin A and its fragments
11. Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma
12. Reporting results of cancer treatment
13. Natural history of neuroendocrine enteropancreatic tumors
14. Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract
15. 111In-pentetreotide: Initial observations and future directions
16. Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review
17. In-111-octreotide therapy: Phase I-II trial
18. 1]-octreotide in patients with neuroendocrine tumors: Evaluation of therapeutic and toxic effects
19. 111In-octreotide therapy in patients with disseminated neuroendocrine tumours
20. 111In-pentetreotide. State of the art and perspectives
21. Yttrium-90-labelled somatostatin-analogue for cancer treatment
22. Yttrium-90 DOTATOC: First clinical results
23. 3-octreotide: Preliminary report in cancer patients
24. OctreoTher: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy
25. 3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
26. 3-octreotide
27. Safety and efficacy of [Y-90-DOTA, Tyr(3)]octreotide (Y-90-SMT487; OCTREOTHER™) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study
28. 0]octreotide in patients
29. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver
30. Peptide receptor radionuclide therapy (PRRT) using somatostatin analogs
31. The long-term hazards of the treatment of thyroid cancer with radioiodine
32. Induction of leukemia by 131-I treatment of thyroid carcinoma
33. Leukaemia incidence after iodine-131 exposure
34. Leukaemias and cancers following iodine-131 administration for thyroid cancer
35. Somatostatin receptors in the haematopoietic system
36. Acute renal failure
37. The localization of messenger ribonucleic acids for somatostatin receptors 1, 2, and 3 in rat testis
38. Serum inhibin B as a marker of spermatogenesis
39. Testicular function after radioiodine therapy for thyroid carcinoma
40. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms